ABSTRACT
INTRODUCTION

36
Tissue copper concentrations and distribution in the body must be tightly controlled to 37 ensure delivery of copper to essential cuproenzymes such as cytochrome c oxidase and lysyl 38 oxidase without causing toxicity due to the formation of free radicals promoted by free copper 39 ions. Background literature concerning copper homeostasis has been discussed in detail in a 40 book by Linder (17) . The importance of copper homeostatic mechanisms is graphically 41 illustrated by the severity of the genetic disorders of copper homeostasis, Menkes and Wilson 42 diseases. Menkes disease is a fatal X-linked copper deficiency disorder, which presents with a 43 wide range of symptoms, including neurodegeneration, connective tissue defects and abnormal 44 hair. Most Menkes patients die in early childhood and have abnormally low copper 45 concentrations in many tissues eg. the brain, liver, heart but paradoxically some tissues 46 accumulate copper (eg. kidney and small intestine) (8) . Wilson disease is an autosomal 47 recessive copper toxicity disorder, in which copper accumulates to extremely high 48 concentrations in the liver, and can result in liver failure or neurological defects due to copper 49 deposits in the central nervous system. Wilson disease is potentially fatal but can be treated 50 with copper chelators (8, 17) . 51
The identification of the genes affected in Menkes disease (5, 21, 37) and Wilson disease (3, 52 33, 39) , provided the first important insights into the molecular basis of copper homeostasis. 53
These genes encode closely related Cu-transporting P-type ATPases with 67% amino acid 54 identity (2). The Menkes gene ATP7A encodes the Menkes protein ATP7A and the Wilson gene, 55 ATP7B, encodes the Wilson protein ATP7B. Many disease-causing mutations have been found 56 in both genes, and in most cases are predicted to almost completely abolish the copper 57 7 Antibodies -Despite the inclusion of the myc epitope in the ATP7a construct, the myc antibody 122 did not prove reliable for detecting the ATP7A in the transgenic mice. Therefore we use 123 antibodies raised to ATP7A which detect both endogenous and transgenic proteins. The ATP7A 124 antibodies were raised in sheep against the first 590 N-terminal amino acids consisting of the 125 six copper binding domains fused to a (His) 6 tag at the N-terminus. Affinity-purified antibody 126 (R17-BX) was isolated from the sodium sulfate IgG precipitated fraction by immunoaffinity 127 chromatography using the 590 N-terminal amino acids of ATP7A coupled to CNBr-activated 128 beads (Sigma-Aldrich, Castle Hill, NSW, Australia). 129
130
Western blot analysis -60 day old mice were sacrificed by CO 2 asphyxiation, and various 131 tissues (lung, heart, liver, kidney, small intestine and brain) were collected and frozen 132 immediately on dry ice. Tissues were ground in liquid nitrogen with mortar and pestle, and 133 homogenized in extraction buffer containing 6% SDS, 0.14M Tris-HCl, pH 6. 8 
RESULTS
198
CAG-ATP7A construct -Our previous studies on the expression of ATP7A from a cDNA 199 construct in cultured mammalian cell had shown a low expression frequency (16) (Fig. 1A) was introduced into one cell stage embryos by pronuclear 212 injection and the two cell stage embryos transferred to recipient females using standard 213 procedures. Potential ATP7A transgenic (CAG-ATP7A) founder mice were screened by PCR of 214 genomic DNA from tail biopsies as described in Materials and Methods. Ten independent 215 CAG-ATP7A founders were identified from 22 pups born. Breeding colonies were established 216 from a number of these founders by mating with C57BL/6 mice. Two lines, T22#2 and T25#5 217
were selected for detailed analysis. Homozygote T25#5 females could not be generated, 218 therefore all experiments were performed with heterozygous CAG-ATP7A mice, with the use of 219 wild type littermates as controls. The transgenic mice displayed no overt phenotype resulting 220 from the expression of the human ATP7A protein. Male and female mice transmitted the 221 transgene to their progeny, and their behaviour, growth rate and lifespan was similar to non-222 transgenic littermates. Furthermore, the internal organs from non-transgenic and transgenic 223 mice were similar in size and appearance. 224
225
Western blot analysis of transgene expression -Western blot analysis of proteins from six 226 organs (lung, heart, liver, kidney, small intestine and brain) was carried out as described in 227
Materials and Methods. The affinity purified anti-ATP7A R17-BX antibody detected a band at 228 about 178 KDa in most tissues of the transgenic mice, consistent with the size of ATP7A (28) 229 ( Fig. 1B) . The same blots were stripped and reprobed with calnexin to provide an estimate of 230 the protein loaded in each lane and allow a comparison of the levels of ATP7A with the 231 endogenous Atp7a in transgenic and non-transgenic tissues. Atp7a was barely detectable in the 232 non-transgenic mice, with clear signals being seen only in lung, kidney and brain. In both 233 transgenic lines the highest level of ATP7A was seen in the heart, with moderate expression in 234 the kidney, small intestine and brain. The two lines had a similar pattern of expression except 235 for higher expression of ATP7A in the lung of T25#5 and more ATP7A was seen in the liver of 236 the T22#2 line. It was difficult to quantify the degree of over-expression of the protein in the 237 transgenic animals due to the low endogenous levels, so we used real time PCR to estimate the 238 relative expression levels. 239
240
Relative levels of ATP7A and Atp7a mRNA -Total RNA was isolated from tissues and real time 241 PCR was conducted with primers that were specific for the endogenous mouse Atp7a and the 242 human ATP7A. Table 1 shows the levels of ATP7A relative to Atp7a. In all tissues there was 243 considerable over-expression of ATP7A mRNA from the transgene, and the amounts were 244 generally consistent with the pattern of expression shown in the Western blots. The relative 245 levels of ATP7A mRNA to Atp7a mRNA was highest in the heart with up to 200 fold increase 246 being observed in some animals. There was considerable variation in ATP7A mRNA between 247 animals, probably due to the mosaicism of expression (see below). 248
249
Immunohistochemical analysis -To detect the cellular pattern of expression of ATP7A, tissue 250 sections were incubated with the R17-BX antibody as described in the Materials and Methods. 251 13 Endogenous Atp7a was not detectable under the conditions used ( Fig. 2A, D , G, J, M). In both 252 lines a variable mosaic expression pattern of ATP7A was observed in most tissues and the 253 pattern of expression differed between individual mice (data not shown). In kidney of T22#2 254 mice (Fig. 2B) , ATP7A immunoreactivity was localized predominantly in tubules with 255 morphology consistent with distal tubules, whereas in T25#5 the staining was less pronounced 256 in tubules. The immunostaining appeared in the podocytes in the glomerulus (Fig. 2C) and in 257 the macular densa of the distal tubules as well as the thin loops of Henle and the outer medulla, 258 there appeared to be little staining in the proximal tubules (data not shown). Strong ATP7A 259 immunoreactivity was detected in the perinuclear region of the enterocytes in the small intestine 260 of both lines (Fig. 2E and F) . Transgenic protein was immunolocalized in patches in the liver 261 hepatocytes ( Fig. 2H and I ) where endogenous Atp7a is not usually expressed (26). 262
Interestingly the protein appeared localized to the plasma membrane of hepatocytes, in contrast 263 to the cytoplasmic perinuclear labels seen in other cell types. Immunostaining was observed in 264 the smooth muscle cells of lung blood vessel (Fig. 2K and L) and the cardiac muscle cells of the 265 heart displayed strong staining (Fig 2N and O) , consistent with the high expression noted on 266
Western blots, but even in the heart the mosaic expression was still noted (Fig. 2N and O) . 267
Because of the importance of the brain abnormalities in Menkes disease, we made a more 268 detailed analysis of the expression pattern of the transgene in this organ in 60 day old T22#2 269 and T25#5 mice. Since very similar staining patterns were observed in both lines, only sections 270 of T22#2 line are shown (Fig. 3) and as for the other tissues analyzed the endogenous protein 271 was not detected under the condition used (data not shown). Strong immunoreactivity was 272 observed predominantly in CA2 region of the hippocampus (Fig. 3A and B) , the Purkinje cells 273 14 of the cerebellum (Fig. 3C and D) and the choroid plexus ( Fig. 3E and F) . The staining was 274 cytoplasmic and perinuclear, consistent with the location in the transGolgi network. 275
Immunostaining was also seen in CA1, CA3 regions, dentate gyrus, and ependymal cells of the 276 hippocampus (data not shown). 277
278
Tissue copper concentrations -To determine whether the over-expression of human Menkes 279 protein altered copper homeostasis in the transgenic mice, copper concentrations in tissues from 280 60 and 300 day normal and transgenic mice were determined by atomic absorption 281 spectrometry. As can be seen in Fig. 4 , the overall effect of the transgene expression was to 282 deplete tissue copper, an effect which became more marked as the animals aged and was most 283 pronounced in the heart and brain. In general the T22#2 line was more severely depleted. 284
Copper concentrations in the heart were decreased in both young and old transgenic mice 285 compared to normal mice with the reduction more pronounced in the older group and the effect 286 was more significant in the females. In the 300 day old T22#2 females the copper concentration 287 was decreased by 24% compared to normal females (17.61±3.47 µg/g v 23.23±2.09 µg/g dry wt, 288 p<0.001, Student's t-test). A similar reduction in cardiac copper was apparent in the older 289 T25#5 females. The older T22#2 males showed an 18% reduction in copper concentration 290 (18.33±4.19 µg/g compared with 22.44±1.66 µg/g dry wt in non-transgenics, p=0.03, Student's 291 t-test). Liver copper was significantly deficient in 60 day old T22#2 female mice (10.80±1.29 292 µg/g v 14.44±1.44 µg/g dry wt, P<0.001 Student's t-test), but the hepatic copper concentrations 293 in female 60 day old T25#5 mice was not reduced. The lowering of liver copper was still 294 significant at 300 days in the T22#2 females, but again the T25#5 female hepatic copper was 295 15 the same as the non-transgenic group. All 60 day old male mice had higher hepatic copper 296 concentrations than females of this age, however, the transgenic mice did not differ from the 297 non-transgenics. Kidney copper concentrations were reduced in the T22#2 mice but this 298 reduction was only significant in the 60 day old males, and the 300 day old females. The T25#5 299 line did not display a reduction in kidney copper, perhaps relating to the different pattern of 300 expression in this organ between the two lines (Fig. 2) . Small intestine copper concentrations 301 were slightly reduced in the older T22#2 female transgenic mice (7.85±0.75 µg/g v 9.48±1.29 302 µg/g dry wt, P<0.05, Student's t-test), with a similar reduction in the males of this age. Most studies of the copper transport functions of ATP7A have been carried out in cultured 323 cells in which the Menkes protein was expressed at a high level to facilitate easy detection 324 using immunofluorescence microscopy, as in many cell types the endogenous ATP7A is too 325 low for detailed analysis. The ATP7A over-expressing cell lines revealed that the protein was 326 stimulated to move from the transGolgi network to the plasma membrane when cells were 327 exposed to elevated copper (28). Over-expression of the protein was also found to confer 328 copper resistance to the cells, because of enhanced ability to efflux copper (4). We proposed 329 that Cu-induced trafficking of ATP7A represented a central homeostatic mechanism that 330 maintains intracellular copper levels within safe limits and suggested that this mechanism 331 would also regulate copper balance in the whole animal. We found that the levels of ATP7A in 332 tissues in mice are too low for studies of the localization of the protein, so the question of 333 whether the trafficking of the Menkes protein is a physiological phenomenon could not be 334 readily answered. 335
To help overcome the problems of detection, and to investigate the effects of over-expression 336 of ATP7A, we have developed some lines of transgenic mice in which the human ATP7A is 337 expressed from the CAG promoter. Although the expression of ATP7A in the transgenic mice 338 does not exactly match that of the endogenous Atp7a, our results here, for two lines T22#2 and 339 T25#5 show that the expression pattern of the transgenic protein is quite similar to the 340 endogenous protein, with two major differences: the Menkes protein (ATP7A) is expressed in 341 some hepatocytes in the transgenic mice and at high levels in the heart. Messenger RNA levels 342 estimated by real time PCR suggested that the level of expression was highly variable between 343 mice, and this was presumably due to the mosaic expression of the transgene that was evident 344 from the immunocytochemical analysis. In the heart very high levels of expression (up to 197.5 345 fold) were detected using real time PCR but the relative levels of protein could not be estimated 346 as the endogenous protein was not detectable. Despite the increased amounts of ATP7A in cells, 347
there did not appear to be mislocalization of the protein, as in all cells except hepatocytes, the 348 protein appeared to be in a position consistent with the transGolgi network where ATP7A is 349 found in cultured cells not exposed to copper (28). This localization was most clearly seen with 350 the enterocytes of the small intestine (Fig 2E and F) Fig. 2H and I) . We conclude that ATP7A is located in the basolateral surface of 360 these hepatocytes, as the markers on the apical surface (abutting the biliary canaliculus) give 361 
